# US 2013/0158092 A1 · New Oral Formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158092 A1
- Document ID: US20130158092A1
- Status: Published application
- Kind: A1
- Application number: 13/755,444
- Filed: 2013-01-31
- Published: 2013-06-20
- Earliest claimed: 1998-08-21
- Assignees: Novartis AG
- Inventors: Karel De Bruijn; Gunter Engel; Hans-Jurgen Pfannkuche; Michael Thewissen; Christian Vitzling; Othmar Zuger
- Web page: https://patentgrep.com/patent/US20130158092A1

## CPC

- A61K 31/404: Indoles, e.g. pindolol
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/06: Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition, in particular to a composition for administering active agents which are poorly soluble in aqueous media, and/or which are acid sensitive.

## Claims

### Claim at position 1

1-26. (canceled)

### Claim 27

A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof and a disintegrant which is present in an amount of at least 15% by weight based on the total weight of the composition, wherein the disintegrant is a member selected from the group consisting of crospovidone, sodium starch glycolate, carboxymethylcellulose sodium, sodium alginate, and a mixture thereof.

### Claim 28 (depends on 34)

A solid oral pharmaceutical composition according to claim 34 wherein the disintegrant is crospovidone.

### Claim 29 (depends on 27)

A solid oral pharmaceutical composition according to claim 27 further comprising a lubricant.

### Claim 30 (depends on 36)

A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a glyceryl mono fatty acid.

### Claim 31 (depends on 36)

A solid oral pharmaceutical composition according to claim 36 wherein the lubricant comprises a mixture of glyceryl monostearate and polyethylene glycol.

### Claim 32 (depends on 38)

A solid oral pharmaceutical composition according to claim 38 further comprising a surfactant.

### Claim 33 (depends on 39)

A solid oral pharmaceutical composition according to claim 39 wherein the surfactant is a member selected from the group consisting of a polyoxytheylene-sorbitan-fatty acid ester, a polyoxyethylene fatty acid ester, a polyoxyethylene-polyoxypropylene block co-polymer, a reaction product of a natural or hydrogenated castor oil and ethylene oxide, dioctylsuccinate, di-[2-ethylhexyl]-succinate, a propylene glycol mono-fatty acid, and a propylene glycol di-fatty acid.

### Claim 34 (depends on 40)

A solid oral pharmaceutical composition according to claim 40 wherein the surfactant comprises a polyoxyethylene-polyoxypropylene block co-polymer.

### Claim 35 (depends on 41)

A solid oral pharmaceutical composition according to claim 41 further comprising lactose and hydroxypropylmethylcellulose.

### Claim 36 (depends on 27)

A solid oral pharmaceutical composition of claim 27, wherein said pharmaceutical composition has dissolution characteristics in water or USP buffers pH 6.8 and 7.5 of:
time (minutes)
amount (percentage)
5
30-90
15
80-100
30
95-100
60
100.

### Claim 37

A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof and a disintegrant which is present in an amount between 20% and 60% by weight based on the total weight of the composition, wherein the disintegrant is carboxymethylcellulose calcium.

### Claim 38 (depends on 44)

A solid oral pharmaceutical composition according to claim 44 wherein the pharmaceutically acceptable salt is the maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

### Claim 39

A solid oral pharmaceutical composition comprising 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide or a pharmaceutically acceptable salt thereof and a disintegrant which is present in an amount between 30% and 50% by weight based on the total weight of the composition, wherein the disintegrant is pregelatinized starch.

### Claim 40 (depends on 46)

A solid oral pharmaceutical composition according to claim 46 wherein the pharmaceutically acceptable salt is the maleate salt of 3-(5-methoxy-1H-indol-3-yl-methylene)-N-pentylcarbazimidamide.

### Claim 41 (depends on 27)

A solid oral pharmaceutical composition according to claim 27 wherein said composition is a tablet.

### Claim 42 (depends on 35)

A solid oral pharmaceutical composition according to claim 35 wherein said composition is a tablet.

### Claim 43 (depends on 45)

A solid oral pharmaceutical composition according to claim 45 wherein said composition is a tablet.

### Claim 44 (depends on 47)

A solid oral pharmaceutical composition according to claim 47 wherein said composition is a tablet.
